A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.
|Videos|June 1, 2017
Use of SBRT in Treating Pancreatic Cancer
Author(s)Sarah E. Hoffe, MD
This video highlights the evolution of stereotactic body radiation therapy in the treatment of pancreatic cancer.
Advertisement
In this video, Sarah E. Hoffe, MD, of the Moffitt Cancer Center in Tampa, Florida, discusses the evolution of stereotactic body radiation therapy (SBRT) for the treatment of pancreatic cancer.
Hoffe also highlights a recent study
Advertisement
Related to this article
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Data from the phase 3 HARMONi-GI1 trial support first-line ivonescimab plus chemotherapy as a new standard of care in advanced biliary tract cancer.
Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma in CLARITY-Gastric01.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
A cisplatin-free pembrolizumab regimen yielded 65.1% laryngectomy-free survival rate at 2 years in SMART-KEY, missing significance vs historical controls.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
3
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
4
Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC
5